Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
2005-03-18
2010-02-09
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C424S451000, C424S455000, C514S348000, C514S365000
Reexamination Certificate
active
07658943
ABSTRACT:
The invention described herein relates to a pharmaceutical composition containing vinorelbine as an active ingredient which is suitable for encapsulation in soft capsules. The liquid oral pharmaceutical composition suitable for a liquid fill composition for a soft capsule dosage form comprises: vinorelbine or a pharmaceutically acceptable salt thereof; ethanol; water; glycerol; and polyethylene glycol. In a preferred embodiment, the tartrate salt form of vinorelbine is used in the composition. The invention also provides for a method of treating cancer comprising orally administering, to a patient in need of treatment thereof, a soft capsule comprising the pharmaceutical composition of the invention.
REFERENCES:
patent: 3097137 (1963-07-01), Beer et al.
patent: 4623629 (1986-11-01), Kerschensteiner
patent: 4708834 (1987-11-01), Cohen et al.
patent: 5114919 (1992-05-01), Baldwin et al.
patent: 5292512 (1994-03-01), Schaefer et al.
patent: 5447936 (1995-09-01), Hausheer et al.
patent: 5620985 (1997-04-01), Jacquesy et al.
patent: 5645856 (1997-07-01), Lacy et al.
patent: 5674873 (1997-10-01), Hausheer et al.
patent: 5674874 (1997-10-01), Hausheer et al.
patent: 6011041 (2000-01-01), Schmidt et al.
patent: 6127377 (2000-10-01), Duflos et al.
patent: 6197760 (2001-03-01), Struck
patent: 6235761 (2001-05-01), Hartman et al.
patent: 6262093 (2001-07-01), Camden
patent: 6310039 (2001-10-01), Kratz
patent: 6890558 (2005-05-01), Bougaret et al.
patent: 0317401 (1989-05-01), None
patent: 375520 (1993-04-01), None
patent: 010458 (1998-04-01), None
patent: 9418977 (1994-09-01), None
patent: 0059473 (2000-10-01), None
Zhou et al, Biopharmaceutics & Drug Disposition, vol. 15 1994.
Zhou et al, Relative Bioavailability of Two Oral Formulations of Navelbine in Cancer Patients, 1994, Biopharmaceutical& Drug Disposition, vol. 12, 577-586.
Zhou et al, Relative Bioavailability of Two Oral Formulations of Navelbine in Cancer Patients, 1994, Biopharmaceutics & Drug Disposition; vol. 12, 577-586.
Cohen, Relat8ive Bioavailability of two oral formulations of navelbine in cnacer patients, 1994, Biopharmacetucis & Drug Disposition, vol. 15, 577-586.
Zhou et al (Biopharmaceutics & Drug Disposition, vol. 15, 1994.
Favre, R., et al., “Phase I Trial Of Escalating Doses Of Orally Administered Navelbine (NVB): Part ll- Clinical Results,” Proc. Am. Chem. Clin. Oncol., vol. 8, p. 64 (abstr.) (1989).
Rahmani, R., et al., “Oral Administration Of [3H]navelbine In Patients: Comparative Pharmacokinetics Using Radioactive And Radioimmunologic Determination Methods,” Anti-Cancer Drugs, vol. 2, pp. 405-410 (1991).
Winer, E., et al., “A US Multicenter Phase II Trial Of Oral Navelbine In Elderly Women With Advanced Breast Cancer,” Breast Cancer Res. Treat., vol. 27, p. 136 (1993).
Bercez, C., et al., “Medico-economic Evaluation Of Breast Cancer Adjuvant Treatment,” San Antonio Breast Cancer Symposium, pp. 203, 258 (abstr.) (1996).
Variol, P., et al., “Pharmacokinetics Of Oral Vinorelbine in Women With Advanced Breast Cancer,” Proc. Am. Assoc. Cancer Res., vol. 37, pp. 179, 707 (abstr.) (1996).
van Cantfort, J., et al., “Systemic Bioavailability And Pharmacokinetic Of Orally Administered Navelbine (NVB): Pilot Study,” Invest. New Drugs, vol. 7, Abstract 447 (1989).
Spicer, D., et al., “Oral Navelbine (NVB) in Women With Previously Treated Advanced Breast Cancer (ABC): A US Multicenter Phase II Trial,” Proc. Ann. Meet. Of Amer. Soc. Clinical Oncol., vol. 13, A 105 (abstr.) (1994).
Chevallier. B, et al., “Phase I Clinical Trial Of Oral Vinorelbine In Patients With Advanced Breast Cancer: Preliminary Results,” San Antonio Breast Cancer Symposium, pp. 213, 286 (abstr.) (1996).
Bonneterre. J, et al., “Phase I and Pharmacokinetic Study Of Weekly Oral Therapy With Vinorelbine In Patients With Advanced Breast Cancer (ABC)”, Ann. Oncol., vol. 12(12), pp. 1683-1691 (abstr.) (Dec. 2001).
Fellous et al., “Biochemical Effects of Navelbine on Tubulin and Associated Proteins”,Seminars in Oncology, vol. 16, No. 2, Suppl. 4 (April) 1989: pp. 9-14.
Fumoleau et al., “UFT Plus Oral Calcium Folinate/Vinorelbine for Advanced Breast Cancer”,Oncology, vol. 13, No. 7, Suppl. No. 3.
Cros et al., “Experimental Antitumor Activity of Navelbine”,Seminars in Oncology, vol. 16, No. 2, Suppl. 4 (April), 1989: pp. 15-20.
Gregory et al., “Vinorelbine—a clinical review”,British Journal of Cancer(2000) 82(12), pp. 1907-1913.
Aapro et al., “Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine”,Critical Reviews in Oncology/Hematology, 40 (2001) pp. 251-263.
Rahmani et al., “Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods”,Anti-Cancer Drugs, 2, pp. 405-410.
Vokes et al., “Multicenter Phase II Study of Weekly Oral Vinorelbine for Stage IV Non-Small-Cell Lung Cancer”,J. Clinical Oncology, vol. 13, pp. 637-644.
Van Cantfort et al., Systemic Bioavailability and Pharmacokinetic of Orally Administered Navelbine (NVB) : Pilot Study (Abst.).
Lucas et al., “Absolute Bioavailability (ABA) and Pharmacokinetics (PK) of Weekly Navelbine (NVB) Liquid-Filled Soft Gelatin Capsules at Full Therapeutic Doses in Patients (pts) with Solid Tumors”, (Abst.).
Fields et al., “Phase I Clinical Trial of Chronic Oral Navelbine Administration”, (Abst.).
Cvitkovic et al., “A Phase I-II Study of Navelbine (NVB) by 96 Hours Continuous Infusion (CIV) in Metastatic Breast Cancer (MBC)”, (Abst.).
Dieras, et al., “Phase II study of Navelbine (NBV) and Fluoro-uracil (FU) in Metastatic Breast Cancer (MBC) patients using a group sequential design (GSD)”, (Abst.).
Spicer et al., “Oral Navelbine (NVB) in Women with Previously Treated Advanced Breast Cancer (ABC): A US Multicenter Phase II Trial”,Breast Cancer, Proceedings of ASCO vol. 13, Mar. 1994 (Abst.).
Winer et al., “A US Multicenter Phase II Trial of Oral Navelbine in Elderly Women with Advanced Breast Cancer”, (Abst.).
Chevallier et al., “Phase I Trial Oral Vinorelbine (VRL) in Patients (PTS) with Advanced Breast Cancer (ABC)”, (Abst.).
Variol et al., “Effects of Food Study on Pharmacokinetic (PK) Profile and Safety of Oral Vinorelbine (VRL) in Patients (Pts) with Solid Tymors or Lymphomas”,Clinical Pharmacology, Proceedings of ASCO, vol. 17, 1998 (Abst.).
Information Disclosure Statement regarding clinical study and supporting Declaration of Andrew G. Rozycki.
Rowinsky et al., “Pharmacokinetic, Bioavailability, and Feasibility Study of Oral Vinorelbine in Patients with Solid Tumors,” J. Clin. Oncol., 1994, pp. 1754-1763, vol. 12, No. 9.
Zhou et al., “Relative Bioavailability of Two Oral Formulations of Navelbine in Cancer Patients,” Biopharmaceutics & Drug Disposition, 1994, pp. 577-586, vol. 15.
Jassem et al., “A Multicenter Randomized Phase II Study of Oral vs. Intravenous Vinorelbine in Advanced Non-small-cell Lung Cancer Patients,” Annals of Oncology, 2001, pp. 1375-1381, vol. 12.
Bohn Marie-Madeleine
Bougaret Joel
Heintz Norbert
Leverd Elie
Fitzpatrick ,Cella, Harper & Scinto
Hartley Michael G
R.P. Scherer Technologies, LLC
Young Micah-Paul
LandOfFree
Oral pharmaceutical composition for soft capsules containing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral pharmaceutical composition for soft capsules containing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral pharmaceutical composition for soft capsules containing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4151632